home / stock / avxl / avxl news

AVXL News and Press, Anavex Life Sciences Corp. From 01/02/24

Stock Information
Company Name: Anavex Life Sciences Corp.
Stock Symbol: AVXL
Market: NASDAQ
Website: anavex.com
Menu
AVXL AVXL Quote AVXL Short AVXL News AVXL Articles AVXL Message Board
Get AVXL Alerts

News, Short Squeeze, Breakout and More Instantly...
AVXL - NDRA, PYPD and TAOP among mid-day movers

2024-01-02 12:56:48 ET More on Mid-day movers & stocks. ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Endra Life Sciences Historical earnings da...
AVXL - Anavex drops as Phase 3 trial for Rett syndrome candidate fails

2024-01-02 08:40:41 ET More on Anavex Life Sciences How Soon Might Anavex's Alzheimer's Drug Be Approved? The Good/Bad News Anavex Life Sciences: Rett Safety Dance With Broader CNS Implications (Rating Downgrade) Anavex Life Sciences Corp. (AVXL) Q4 2023 Earnings Cal...

AVXL - SXTC, CGA and JFBR among pre-market losers

2024-01-02 08:30:21 ET Losers: Corcept Therapeutics CORT -33% in patent battle with Teva . China SXT Pharmaceuticals ( SXTC ) -29% . Sentage Holdings ( SNTG ) -27% . China Green Agriculture ( CGA ) -23% . Aditxt ( ADTX ) -24% . ...

AVXL - Anavex Life Sciences Provides an Update on Rett Syndrome Program

Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome Validation from Real World Evidence (RWE) of Rett Syndrome Patients under Compassionate Use Authorization NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp....
AVXL - Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...

AVXL - Anavex gets EMA green light to submit blarcamesine application for Alzheimer's

2023-12-19 17:03:56 ET More on Anavex Life Sciences How Soon Might Anavex's Alzheimer's Drug Be Approved? The Good/Bad News Anavex Life Sciences: Rett Safety Dance With Broader CNS Implications (Rating Downgrade) t Anavex Life Sciences falls after Q4 pipeline upd...

AVXL - Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease

NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders,...
AVXL - Alzheimer's Disease Drug Development: Another Lost Year

2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...

AVXL - How Soon Might Anavex's Alzheimer's Drug Be Approved? The Good/Bad News

2023-11-29 07:21:25 ET Summary The EU recommends Anavex proceed with a full approval application for Alzheimer's drug Blarcamesine based on full Phase 2b/3 trial data. The U.S. FDA may grant accelerated approval to Anavex's Blarcamesine based on biomarker data alone. Blarcamesine ...

AVXL - Anavex Life Sciences: Rett Safety Dance With Broader CNS Implications (Rating Downgrade)

2023-11-27 20:52:36 ET Summary ANAVEX2-73 Safety Follow-Up: Extended safety follow-up for Rett syndrome raises concerns but shows commitment to patient safety and scientific rigor. Financial Health: Anavex demonstrates robust short-term liquidity; however, increasing accumulated d...
Previous 10 Next 10